Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Falcon’s Beyond (Nasdaq: FBYD) Acquires Oceaneering Entertainment Systems, Expanding Global Footprint

Falcon’s Beyond Global, Inc. (Nasdaq: FBYD), a leader in immersive storytelling and themed entertainment, today announced it has completed the acquisition of Oceaneering Entertainment Systems (OES), a division of Oceaneering International Inc. (NYSE: OII). The transaction marks a pivotal milestone in Falcon’s strategic growth …

Team Kalkine | 16 May 2025

Churchill Capital Corp X Closes Upsized $414 Million IPO; Begins Trading on Nasdaq as “CCCXU”

Churchill Capital Corp X announced the successful closing of its upsized initial public offering (IPO), raising $414 million through the sale of 41,400,000 units. This total includes 5,400,000 units issued pursuant to the full exercise of the underwriters’ over-allotment option. Each unit was priced …

Team Kalkine | 16 May 2025

CureVac (NASDAQ: CVAC) Gains Second Patent Win Against BioNTech as EPO Upholds mRNA Patent Validity

CureVac N.V. (NASDAQ: CVAC), a global biopharmaceutical leader in messenger RNA (mRNA) innovation, has secured another key legal victory in its ongoing patent litigation against BioNTech SE. The European Patent Office (EPO) has upheld the validity of CureVac’s European patent EP 4 023 755 …

Team Kalkine | 16 May 2025

KKR Real Estate Finance Trust (NYSE: KREF) Continues Strategic Lending and Shareholder Payouts Amid Wider Q1 Loss

KKR Real Estate Finance Trust Inc. (NYSE: KREF)is a real estate investment trust (REIT) focused on originating and acquiring transitional senior loans secured by high-quality commercial real estate (CRE) assets. These assets are typically located in established, liquid markets and owned by experienced sponsors. …

Team Kalkine | 16 May 2025

Markets Retreat as Economic Data Looms; Oil Slumps, Gold Drops, and Earnings Move Stocks

Index Update:U.S. stock futures declined, with the Dow, S&P 500, and Nasdaq all down about 0.4%, as concerns about the economic outlook and anticipation of key data releases—PPI, retail sales, and industrial production—weighed on sentiment. Investors also awaited remarks from Fed Chair Powell for …

Team Kalkine | 15 May 2025

e.l.f. Beauty (NYSE: ELF) Expands Retail Reach in The Netherlands and Belgium Through Kruidvat and Trekpleister

e.l.f. Beauty has announced a retail expansion in the Netherlands and Belgium through partnerships with two major drugstore chains, Kruidvat and Trekpleister. Starting May 26, 2025, consumers in both countries will be able to find e.l.f. Cosmetics and e.l.f. SKIN products on shelves in …

Team Kalkine | 15 May 2025

VEON (Nasdaq: VEON) Reports 1Q2025 Earnings with 50% Digital Revenue Growth and Higher EBITDA

VEON Ltd. (Nasdaq: VEON) has reported its financial and operational performance for the first quarter of 2025, showing revenue and earnings growth alongside expanding digital revenues. The company generated $1.03 billion in revenue, reflecting an 8.9% year-on-year increase in U.S. dollar terms. In local …

Team Kalkine | 15 May 2025

Cancun and Las Vegas Emerge as Top Picks in Tripadvisor's 2025 Summer Travel Index

Tripadvisor has released its 2025 Summer Travel Index, offering a detailed look into how U.S. travelers are preparing for the upcoming vacation season. The data, based on both site analytics and a global survey, suggests a busy summer ahead with 63% of respondents expressing …

Team Kalkine | 15 May 2025

Stardust Power (Nasdaq: SDST) Reports Q1 2025 Financial Results Amid Progress on Muskogee Lithium Facility

Stardust Power Inc. (Nasdaq: SDST), a U.S.-based developer of battery-grade lithium products, released its financial results for the first quarter of 2025, reporting ongoing development activity at its planned Muskogee refinery site and continued investment in early-stage operations.

Team Kalkine | 15 May 2025

AbCellera (Nasdaq: ABCL) Receives Clearance to Begin Phase 1 Trial of ABCL635 for Menopausal Hot Flashes

AbCellera Biologics Inc. (Nasdaq: ABCL) has received a No Objection Letter (NOL) from Health Canada, authorizing the company to proceed with a Phase 1 clinical trial for its investigational drug candidate ABCL635. The study is focused on addressing moderate-to-severe vasomotor symptoms (VMS), commonly referred …

Team Kalkine | 15 May 2025